Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris

<table>IgG reactivity against desmoglein 3 (Dsg3) subdomains in pemphigus vulgaris (PV) patients on rituximab (Rtx). Illustrated is the number of PV patients showing IgG against Dsg3 subdomains before and 6 and 12 months after treatment with Rtx, respectively.</table>

Dermatology Research and Practice

fig2

Figure 2

Figure 2: Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris 